The ongoing intense search for novel and innovative
BASIC CONCEPT
drug delivery systems is predominantly a consequence of the well-established fact that the conventional dosage Since the 1950s, a variety of drugs have been covalently forms are not sufficiently effective in conveying the drug attached to many natural and synthetic polymers. Initially, to its site of action and once in the target area, in the only rationale was that converting the drug into releasing the active agent over a desired period of time. macromolecular prodrug might reduce renal excretion In order to achieve controlled and site-specific drug and hence increase the duration of activity. At that time delivery two approaches have been attempted. One of there was little concern about the cellular uptake and these approaches is pharmaceutical approach, which processing of these conjugates. In 1975, Ringsdorf 3 involves coating the drugs with pH-dependent polymers, proposed a more rationalized model for macromolecular time-dependent delivery systems, biodegradable coatings prodrugs ( fig. 1 ). He upgraded the potential of this and embedding the drugs in therapeutic systems like concept by calling attention to the possibility of liposomes or microspheres 1 . The other approach involves introducing onto the polymer carrier not only the drug chemically based delivery systems like prodrug approach, moiety but also groups that can influence the solubility in which a latentiated drug derivative is prepared, which is inactive as such but yields active drug after activation in mammalian systems by chemical or enzymatic pathway 2 . The potential use of macromolecular prodrugs as a means of achieving targeted drug delivery has attracted considerable interest in recent years. Macromolecules such as antibodies, lipoproteins, lectins, proteins, polypeptides, polysaccharides, natural as well as synthetic polymers offer potential applicabilities as high molecular weight carriers for various therapeutically active compounds.
properties as well as groups that can alter the body distribution and promote cell selectivity.
In this model, the polymeric carrier can be either an www.ijpsonline.com inert or a biodegradable polymer. The drug can be fixed directly or via spacer group onto the polymer backbone. If the polymeric conjugate is pharmacologically active as a whole, the product can be regarded as polymer drug.
Conjugates that are active after release of parent drug are termed as macromolecular prodrugs. Proper selection of the spacer provides the possibility of controlling the site and rate of release of active drug from conjugate by hydrolytic or enzymatic cleavage. The most interesting aspect of this model is the possibility of altering body distribution and cell uptake by attaching cell specific or Native dextran is a polymer of high molecular weight ranging between 10 7 to 10 8 . Its molecular weight can be reduced by acid hydrolysis irrespective of the nature of acid used. Native dextran also possesses high degree of polydispersibility. The value of optical rotation for aqueous solutions of various dextrans varies from +199° to +235°. The intrinsic viscosity is affected by the nature and pH of solvent, degree of branching, number of intermolecular bonds and temperature 7 .
Chemistry:
non-specific uptake enhancers (homing device). This Dextran ( fig. 2) is the generic name applied to a large model has been an important milestone in the history of class of α-D-glucans with anhydro-D-glucopyranose units polymeric prodrug design.
as a part of their main molecular chain. The predominance of α-1,6-linkages is a common feature of Dextrans, which belong to the group of polysaccharide dextrans 8 . Pharmaceutically, the most important dextrans macromolecular carriers devoid of selective transport are composed of 95% α-1,6-glucopyranosidic linkages properties, may serve as one of the most promising and 5% 1,3-linkages. 
Physical properties:
Dextrans obtained from different sources differ in their structure and properties i.e. molecular weight, degree of branching, relative quantity of particular type of glycosidic links, solubility, optical activity and physiological action. Dextrans are soluble in water, formamide and dimethylsulfoxide and insoluble in alcohol and acetone. 
Dextran small molecule complexes:
Carboxymethyl dextran ( fig. 3 (a) ), dextran sulphate ( fig. 3  (b) ), and diethylaminoethyl dextran (DEAE) ( fig. 3 (c) ) are the charged dextran derivatives that form complexes with weight. Dextrans of the molecular weight less than 70,000 various chemical entities. Various hormones like oxytocin have rapid elimination rates during the first hour after and vasopressin have been linked to dextran so as to injection followed by a slower decrease in increase their water solubility along with retention of their concentration 13 . Dextrans with molecular weight in the activity 17 . Attempts to enhance the lymphatic uptake of range 70,000-2,50,000 show prolonged survival in bleomycin 18 by complexation with dextran sulphate after circulatory system. The high polarity of dextrans i.m. and oral administration have been reported. Improved excludes their transcellular passage and their size therapeutic efficiency of isometamidium 19 prevents their passage through gastrointestinal tract. nephrotoxicity of gentamicin 20 Dextrans are depolymerised by the enzyme dextranase these drugs were administered in the form of dextran present in intestine.
sulphate complexes. Enhancement of uptake of proteins and nucleic acids by cells 21 and of interferon production 22 
DEXTRAN CONJUGATES
has been reported by complexation with DEAE dextran.
Dextran conjugates can either be irreversibly linked or Dextran metal complexes: reversibly linked. Irreversibly linked dextran conjugates
Complexes of dextran with heavy metals like iron and are obtained by immobilization techniques and include antimony are relatively easily obtained by reacting metal dextran enzyme conjugates, dextran hormone complexes salts with the polymer in aqueous solution followed by and dextran metal complexes. Reversible dextran precipitation of the macromolecular derivatives with conjugates include dextran esters, dextran ethers and alcohol. Parenteral iron-dextran has been used for the dextran amides.
rapid regeneration of the red cell mass in anemia and in patients, intolerant of oral forms of iron 23 . Pentavalent
IRREVERSIBLE DEXTRAN CONJUGATES
antimonials are quite effective in the treatment of leishmaniasis, but they are rapidly excreted in urine and Dextran derivatives, in which the ligand is irreversibly have short duration of action. So, antimony has been linked to the carrier, have been employed extensively in complexed with dextran, which after intramuscular experimental medicine and find wide applications in the injection is slowly absorbed from injection site and hence and reduced has been reported when field of biotechnology and related areas 14 . Some examples are summarized below:
Dextran enzyme conjugates:
Enzymes are natural regulators of biochemical processes and the potential of enzyme therapy is now accepted in almost every field of medicine. In order to couple enzymes to dextran polymers, number of mild reactions have been adapted that were initially developed for 2 immobilization of enzymes on insoluble polysaccharide
support. This approach has been useful in obtaining sufficient blood levels are maintained so as to suppress the Leishmania donavani infection effectively 24 . Cisplatinum (II) has been complexed with carboxymethyl dextran and is reported to be cytotoxic in vitro against 5 murine and 2 human derived tumor cell lines 25 . www.ijpsonline.com Dextran conjugates are easy to characterize due to homogenous structure of dextran. Even at excessive ligand incorporation high water solubility is restored.
REVERSIBLE DEXTRAN CONJUGATES (PRODRUGS)

Models for covalent drug fixation to dextran
Dextran can be attached to the drug to form a prodrug by various techniques like direct linkage, attachment through intercalated spacer arm, use of modulator ligand and tissue specific receptor ligand 26 . In Direct linkage model, drug is directly linked to dextran, which would release the active agent in a predictable manner. The regeneration of the parent drug would be exclusively governed by the pH dependent hydrolysis, as the bulky dextran matrix would be inaccessible to enzymatic attack. Intercalation of a spacer arm between the drug and the carrier may serve three purposes. First, the terminal functional group of the spacer arm can be varied, thus allowing covalent drug fixation to be established through a variety of chemical bonds. Second, steric hindrance of enzyme activation of the liganded drug might be circumvented by augmenting the distance between the drug and the dextran backbone. Third, sequentially labile the targeted site, a homing device or target specific moiety like antibody or hormone can be incorporated in the model.
MECHANISM OF ACTIVATION FOR DEXTRAN PRODRUGS
The active drug is released from the dextran prodrug by the cleavage of the covalent bond existing between drug and the carrier moiety (dextran) that can be pH dependent or enzymatic 27 . If the drug contains a hydrolysable chemical bond, it might deteriorate while still attached to the polymer backbone. The ability of bulky dextran molecule to suppress catabolism of attached drug/ enzyme has been exploited extensively 27 . Enzymatic partial disrupture of the main chains of dextran prodrugs (without affecting the carrier drug bond) will change the molecular weight distribution of the originally administered prodrug, thus making it susceptible to the attack of various hydrolases 28 .
SYNTHESIS OF DEXTRAN CONJUGATES
Direct esterification 29 :
The dextran ester prodrugs of several drugs like Periodate oxidation method 31 ( fig. 7 ): Dialdehyde dextran is obtained by periodate oxidation of dextran, which is condensed with amino compounds yielding schiff bases. The subsequent reduction with sodium borohydride is performed in order to stabilize the conjugate.
Carbamate ester method 32 :
The carbamate ester liganded conjugates exhibit prolonged duration of activity and reduced toxicity in proportion to the free drug. The principal routes to obtain dextran carbamate ester linkages are depicted in fig. 8 .
Cyanogen bromide activation method 33 :
The cynogen bromide activation of dextran is probably the most widely used reaction to achieve covalent attachment of compounds possessing an amino function to dextran ( fig. 9) .
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APPLICATIONS OF DEXTRAN CONJUGATES Improved in vitro Physico-chemical properties:
The tendency of enzymes to undergo autolytic degradation and thermal lability might be partly circumvented by coupling them with dextran. , α-amylase 35 the development of solid dosage forms for delivery of inflammatory bowel disease, but absorbed rapidly in drugs to colon, as it is inhabited by a large number and stomach and small intestine so that only a negligible variety of bacteria, which secrete many enzymes like β-amount reaches to colon. To overcome this problem a D-glucosidase, β-D-galactosidase, amylase, pectinase, number of azo-coupled dextran-5-ASA prodrugs ( fig. 10 ) xylanase, β-D-xylosidase and dextranase 41 . So have been synthesized 43 , which effectively deliver 5 formulation of a drug-saccharide conjugate (prodrug) is ASA to colon. Dextran-nalidixic acid ester (dextran-NA) an important approach for targeting drugs to colon.
was developed as colon specific prodrug 44 . When Among the various polysaccharides, dextran is an release studies were performed in HCl buffer (pH 1.2) important carrier for delivery of drugs to colon 42 . 5-and phosphate buffer (pH 6.8) at 37° NA was not Aminosalicylic acid (5-ASA) is an effective drug for detected during 6h of the incubation period, which www.ijpsonline.com indicated that dextran-NA might be chemically stable during the transit through the gastrointestinal tract. When dextran-NA was incubated with cecal contents of rats at 37°, the extent of NA released in 24 h was 41% of the dose. Dexamethasone-succinate-dextran (DSD) was synthesized by attaching dexamethasone to dextran (Molecular mass 70,400 Dalton) using succinic anhydride as a spacer. It was found to deliver dexamethasone specifically to colon 45, 46 . Methylprednisolone has been covalently attached to dextran using succinic acid and glutaric acid as the linkers 47, 48 . The hydrolysis kinetic further through tissues, methotrexate (MTX)-dextran conjugates have been synthesized by covalently linking MTX to dextran through a short-lived ester bond (MTX ester-dextran) and a longer-lived amide bond (MTX amide-dextran). The ability of these agents to kill cells and to penetrate through tissue has been evaluated. The cytotoxicity of MTX-ester-dextran and MTX-amide dextran was found equivalent to unmodified MTX. Intracranial polymeric delivery of MTX or MTX-amide dextran to rats with intracranial 9L gliosarcoma produced modest but significant increases in survival; conjugation of studies show that conjugation with dextran helps to MTX to dextran appeared to shift the dose-response deliver the drug to large bowel.
curve to a lower dosage 49 .
Targeting to tumor cells:
Synthesis of dextran conjugate of sodium phenylacetate Even though number of agents effective in killing (NaPA) with substituted dextrans like dextran-methylneoplastic cells are available, their utility in the treatment carboxylate-benzylamide (LS17-DMCB) has been of cancer is often limited by their cytotoxicity towards reported, which shows better tumor inhibition effect proliferating normal cells as well. Numerous studies over against human tumor melanoma 1205LU cells than NaPA the past 40 years have reported an apparent passive alone 50 . A dicarboxymethyl-dextran conjugate of cisplatin targeting of soluble macromolecules to solid tumors due to has been synthesized by immobilizing cisplatin to dextran enhanced permeation and retention (EPR effect) of through six-membered chelate type coordination bond, macromolecules by tumors. Additionally, macromolecular which shows significantly longer half life and better tumor drug carrier systems have been developed in an attempt growth inhibitory activity than plain cisplatin in colon 26 to enhance the selectivity of action of cytotoxic drugs by cancer cells 51 . A macromolecular prodrug of cisplatin coupling them to carriers with expected affinity for the using dextran carrier, having branched galactose units target tissue. Large molecular weight polysaccharides with has been synthesized for targeting to hepatoma cells with molecular mass greater or equal to 40 kD have low successful results 52 . clearance and relatively long plasma half-life, resulting in accumulation in tumor tissues 12 .
Clinically available camptothecins (CPTs) like irinotecan (CPT-11) and topotecan represent one of the most For antitumor agents introduced directly into the promising classes of antitumor agents. In order to intracranial space, the extent of penetration into the tissue improve their pharmacological profile, a new and hence the effectiveness of the therapy depends on macromolecular prodrug denoted T-0128 was the rate of drug elimination from the tissue. To test the synthesized which consists of a novel CPT analogue Thypothesis that slowly eliminated agents would penetrate 2513 conjugated to carboxymethyl dextran via a triglycine spacer 53 . This conjugate shows better www.ijpsonline.com and is a potential target for therapy with radionuclides. The intravesically administered EGF-dextran conjugate EGF-dextran99m
Tc selectively accumulates in the tumor tissue and shows better activity than 99m Tc alone 57 .
Targeted antimycobacterial therapy:
The treatment of tuberculosis requires long-term antibiotic therapy. Targeted antibiotic therapy improves the efficacy of treatment by concentrating the drugs close to mycobacterium. For this purpose, norfloxacin has been linked to mannosylated dextran using peptide spacer arm.
of being rapidly eliminated from the systemic circulation.
When it is conjugated with dextran, the drug is gradually released from the polymeric support leading to a prolonged presence of the active substance in the body, which lowers triglyceride levels 66 .
pH-controlled intracellular drug release:
Polymers like dextran on entering the endosomal or lysosomal compartment are exposed to an acidic medium (pH 4.5-5.5). Using acid cleavable spacers ( fig. 11 ) like hydrazon spacer and N-cis-aconityl spacer between the This conjugate shows more efficacy against drug and the carrier, a pH controlled intracellular drug mycobacterium than plain norfloxacin 58 .
release can be obtained 67 . Streptomycin has been linked to dextran via carboxylic hydrazone linkage for its Antileishmanial targeted therapy: intracellular delivery 68 . Pyrimethamine is effective in antileishmanial therapy due to its ability to inhibit both the enzymes of leishmanial Pharmacodynamic applications; modification of folate pathway, but in vivo this effect occurs only at high immunogenecity of peptides: concentration, which is associated with toxicity. To When proteins or peptides are conjugated to overcome this problem, a prodrug of pyrimethamine macromolecules, the resulting conjugate takes form of a namely carboxymethyldextran thiomannopyrannoside colloid in most cases and the protein core gets protected pyrimethamine has been synthesized, which shows from interaction with other macromolecular plasma approximately 50% destruction of intracellular amastigotes components by a hydrophilic polymer shield. Thus the with no detectable toxicity to macrophage cells 59 . conjugation decreases the immunogenecity of the protein component and permits repeated administration of foreign Pharmacokinetic application; systemic sustained proteins. This approach is particularly useful when the protein is an enzyme with a low molecular weight The profile of plasma concentration of drugs is an substrate found in plasma. The antigenecity of Limportant determinant of their quantitative access to asparaginase 69 and catalase 70 was substantially suppressed peripheral targets. The plasma concentration is usually when they were conjugated to oxidized dextran and measured as the area under the curve (AUC). In dextran with molecular weight of 40,000, respectively. general, slow renal elimination and metabolic inactivation Spacer linked dextran derivatives of pancreatic RNase promote better access of drugs to remote targets. The showed decreased antigenecity 71 effectiveness of various drugs is limited due to their rapid renal excretion. Conjugation of drugs to Overcoming multidrug resistance: hydrophilic macromolecular carriers like dextran can A major problem of using antitumor agents in cancer prevent rapid renal excretion and restrict the drug drug action:
. entry into cells, thus prolonging their plasma circulation time 60 . Insulin dextran complex when injected intraperitoneally in diabetized rabbits maintains blood glucose levels at normal value over several days 61 . Design of dextran prodrugs with the goal of affording prolonged systemic concentration of the liberated drug after oral administration has been reported for quinidine 62 , ursodeoxycholic acid 63 , ibuprofen 64 and analogues of aspirin 65 . Isoniazid has been conjugated to dextran to form dextran-isoniazid complex, which exhibits prolonged persistence in circulation and reduced acute toxicity in the guinea pigs as compared to the parent drug 26 . Nicotinic acid is an effective hypolipidemic agent, but suffers from the disadvantage www.ijpsonline.com chemotherapy is multidrug resistance, which occurs mainly due to over-expression of the P-glycoprotein (Pgp). This transmembrane glycoprotein encoded by the mdrl gene, functions as an energy dependent efflux pump reducing the intracellular accumulation of anticancer drugs 72 . When the free drugs are administered, they enter the cell by diffusion through the plasma membrane and are recognized by the Pgp pumps. On the other hand when these drugs are conjugated to macromolecular carriers, the drug in the form of polymeric prodrug is taken up by endocytosis and subsequently efflux pumps are
CONCLUSION
Even though dextran prodrug approach is still in its infancy, the results from a number of reports lead to optimism concerning the utility of dextran conjugates to provide feasible drug delivery systems. In recent years, a great deal of knowledge has been accumulated about dextran conjugates, but several properties of dextran prodrugs are still partly recognized. A great deal of progress in this field might arise through identification of the drug target and mode of action, by exploiting intrinsic circumvented in turn reducing the multidrug resistance.
properties of the dextran carrier like protection of the The antitumor antibiotic doxorubicin was conjugated with liganded drug from unwanted biodegradation and control polymeric dextrans of various molecular weights and the of the degradability of the dextran backbone. cytotoxicity of the conjugates against human carcinoma KB-3-1 cells and its multidrug-resistant subclone KB-V-1 www.ijpsonline.com
